Developing Novel Therapies for the Treatment of Schizophrenia, Bipolar Depression, and Other Neuropsychiatric Diseases
We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
About usAn oral small molecule with potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
Learn about LB-102Pipeline
A pipeline that leverages the broad therapeutic potential of LB-102 in schizophrenia, bipolar depression, and other neuropsychiatric diseases.
See our pipelineCareers
Join us as we develop novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
See our open positionsContact Us
For questions about LB-102, our pipeline, careers, and other inquiries, please reach out via the form on our Contact Us page.
Contact us